1. Home
  2. RYTM vs PIPR Comparison

RYTM vs PIPR Comparison

Compare RYTM & PIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • PIPR
  • Stock Information
  • Founded
  • RYTM 2008
  • PIPR 1895
  • Country
  • RYTM United States
  • PIPR United States
  • Employees
  • RYTM N/A
  • PIPR N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • PIPR Investment Bankers/Brokers/Service
  • Sector
  • RYTM Health Care
  • PIPR Finance
  • Exchange
  • RYTM Nasdaq
  • PIPR Nasdaq
  • Market Cap
  • RYTM 4.3B
  • PIPR 4.2B
  • IPO Year
  • RYTM 2017
  • PIPR N/A
  • Fundamental
  • Price
  • RYTM $65.63
  • PIPR $286.54
  • Analyst Decision
  • RYTM Strong Buy
  • PIPR Hold
  • Analyst Count
  • RYTM 12
  • PIPR 3
  • Target Price
  • RYTM $77.50
  • PIPR $286.00
  • AVG Volume (30 Days)
  • RYTM 560.2K
  • PIPR 148.9K
  • Earning Date
  • RYTM 08-05-2025
  • PIPR 08-01-2025
  • Dividend Yield
  • RYTM N/A
  • PIPR 2.01%
  • EPS Growth
  • RYTM N/A
  • PIPR 93.72
  • EPS
  • RYTM N/A
  • PIPR 11.46
  • Revenue
  • RYTM $136,863,000.00
  • PIPR $1,540,130,000.00
  • Revenue This Year
  • RYTM $37.56
  • PIPR $8.46
  • Revenue Next Year
  • RYTM $74.99
  • PIPR $17.89
  • P/E Ratio
  • RYTM N/A
  • PIPR $24.29
  • Revenue Growth
  • RYTM 48.88
  • PIPR 10.55
  • 52 Week Low
  • RYTM $40.46
  • PIPR $202.91
  • 52 Week High
  • RYTM $69.89
  • PIPR $351.80
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 53.08
  • PIPR 63.56
  • Support Level
  • RYTM $60.80
  • PIPR $253.00
  • Resistance Level
  • RYTM $64.00
  • PIPR $286.41
  • Average True Range (ATR)
  • RYTM 1.96
  • PIPR 5.73
  • MACD
  • RYTM -0.13
  • PIPR 1.96
  • Stochastic Oscillator
  • RYTM 44.48
  • PIPR 71.97

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About PIPR Piper Sandler Companies

Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.

Share on Social Networks: